AQP4 and autoimmune disease: There were no significant differences between the two groups in terms of gender, age of onset, follow-up duration, comorbid autoimmune diseases, AQP4-IgG positivity rate, presenting symptoms, number of relapses in the year prior to treatment, pre-treatment ARR, and pre- and post-treatment EDSS scores (p > 0.05).